Redesigning therapies
for psychiatry & neurology
for lives worth living

For patients who have not found effective solutions
for their neurological or psychiatric conditions

Clexio Biosciences is a CNS-first clinical stage company. We are dedicated to developing novel therapies for patients suffering from neurological and psychiatric conditions.

Learn More

Aligning humanity, science and technological innovation
to generate new patient-centric possibilities

We identify points of convergence between patients' needs, validated mechanisms of action and technology, to generate new solutions that can be integrated into patients’ lives.

More Info

A multi-asset pipeline

We are a multi-asset company with a rich and growing pipeline, from preclinical to Phase 2 development stages. We invent new therapeutic modalities, and bring them quickly from an idea to Proof of Concept and then to full clinical development.

Program
Pre clinical
Phase 1
Phase 2
Phase 3

CLE-100
NMDA receptor
antagonist

CLE-400
Potent a2-adrenergic
(and SST4, and H4)
receptors agonist

CLE-600
Dopamine precursor

CLE-500
SPG block

Quick facts

Solid foundations

Started in 2018 with strong financial backing and a broad network of partners worldwide

Driven by the patients

Technological and therapeutic ingenuity to address patients'
unmet needs

Multidisciplinary team

Broad experience in Pharma & Biotech, from early innovation to clinical development & regulatory approvals

Learn More
Skip to content